For research use only. Not for therapeutic Use.
Andecaliximab（Cat No.:I042240）is a monoclonal antibody designed to target and inhibit the protein PD-1 (programmed cell death protein 1), a checkpoint receptor found on immune cells. By blocking PD-1, Andecaliximab enhances the immune system’s ability to recognize and attack cancer cells. This therapeutic strategy is aimed at treating various cancers, including non-small cell lung cancer and other solid tumors, by overcoming immune evasion mechanisms used by tumors. Clinical studies are exploring Andecaliximab’s effectiveness and safety, particularly in combination with other immunotherapies for improved cancer treatment outcomes.
| Catalog Number | I042240 |
| CAS Number | 1518996-49-0 |
| Purity | ≥95% |
